GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Advanced Biomedical Technologies ABMT · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2022

Revenue

$270,991

FY2014FY2022

Net income

−$515,485

FY2014FY2022

Free cash flow

−$734,532

FY2014FY2022

Shareholders' equity

−$7.9m

FY2014FY2022

Income statement

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue$270,991$171,192$123,587$11,657—————
Gross profit$221,879$93,295$71,770$4,061—————
Research and development$186,039$229,709$182,959$263,639$56,512$48,053$57,300$60,202$47,700
Operating income−$179,880−$394,860−$446,624−$604,738−$634,017−$403,613−$461,329−$605,193−$617,754
Net income−$515,485−$729,441−$672,000−$948,820−$953,320−$691,600−$724,737−$862,854−$827,756
Diluted earnings per share-0.01-0.01-0.01-0.00-0.01-0.01-0.01-0.01-0.01

Balance sheet

At each fiscal year end

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Total assets$395,704$448,664$469,226$218,500$142,404$85,447$100,710$165,832$217,614
Cash and short-term investments$4,845$36,978$201,664$5,592$6,860$7,463$6,559$38,304$74,354
Total liabilities$8.3m$8.8m$7.9m$6.7m$5.8m$5.1m$4.5m$4.6m$4.0m
Debt$6.8m$6.9m$4.7m$4.9m$4.3m$3.8m$3.1m$3.5m$3.4m
Shareholders' equity−$7.9m−$8.4m−$7.4m−$6.5m−$5.6m−$5.0m−$4.4m−$4.5m−$3.7m
Shares outstanding71m71m70m275m85m58m63m66m57m

Cash flow

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations−$734,532−$845,613$646,660−$742,530−$832,421−$557,712−$371,653−$820,393−$732,421
Capital spending—−$51,531−$30,706−$18,565−$64,405−$453−$1,699−$32,311−$8,793
Free cash flow−$734,532−$897,144$615,954−$761,095−$896,826−$558,165−$373,352−$852,704−$741,214

Latest quarters

By quarter end

Jul 2022Apr 2022Jan 2022Oct 2021Jul 2021Apr 2021Jan 2021Oct 2020
Revenue−$4,939−$102$281,485$123,684$180$95$47,233$62,336
Gross profit−$7,291−$6,716$241,024$90,725$142$63$37,086$44,350
Operating income−$106,819−$107,269$146,022−$81,296−$111,772−$113,150−$88,642−$110,204
Net income−$189,786−$190,488$58,107−$169,595−$198,713−$189,089−$172,044−$193,334
Diluted earnings per share-0.00-0.000.00-0.00-0.00-0.00-0.00-0.00
Total assets$383,486$393,277$369,927$448,664$396,508$378,688$331,792$469,226
Cash and short-term investments$5,701$29,034$8,414$36,978$6,983$6,008$8,491$201,664
Debt$7.1m$7.1m$7.1m$6.9m$21,652$5.4m$5.3m$4.7m
Shareholders' equity−$8.3m−$8.3m−$8.4m−$8.4m−$8.2m−$8.0m−$7.8m−$7.4m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue185.4%——
Operating income-33.2%-14.9%-11.9%
Net income-18.4%-5.7%-3.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin71.3%67.7%——
Operating margin-130.0%-281.6%——
Net margin-281.5%-496.3%——

Valuation history

At each fiscal year end

FY2022FY2021
Price to earnings-0.1—
Price to sales0.10.0

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return700%-97%18%2599%941%199337%13811%2218%410%7%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-for-1 split · 13 Mar 2009

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.